Latest Asia Pacific Market News

ReNerve has inked an exclusive three-year deal with Hong Kong’s Swedish Trading Company to distribute its nerve repair products across a vast and dynamic healthcare region.

EcoGraf confirms its patented HFfree process offers competitive costs for producing high-purity spherical graphite, targeting non-Chinese battery supply chains with plans for facilities in the US, Europe, and Asia.

VRX Silica’s updated 2026 Bankable Feasibility Study for Arrowsmith North confirms robust economics with an ungeared NPV8 of A$179.2 million and binding offtake contracts securing nearly 1 million tonnes annually.

XReality Group (ASX:XRG) posts strong FY26 revenue and ARR growth, marking key milestones with its first commercial MR-1 mixed reality sale to the US Department of Defense and debut European contract with the Swedish Armed Forces.

Operator XR, a subsidiary of xReality Group, has landed its first European deal supplying a VR tactical training system to the Swedish Armed Forces, marking its debut in NATO markets.

Pacific Edge launches a NZ$6 million retail share offer at NZ$0.17 per share following a NZ$25.4 million institutional placement, aiming to strengthen its balance sheet and support Medicare reimbursement efforts for its bladder cancer diagnostics.

NH3 Clean Energy’s WAH2 Clean Ammonia Project has been granted Federal Major Project Status, accelerating government approvals and supporting a Final Investment Decision by end 2026.

Nexsen Limited teams with Universiti Malaya to launch a joint research facility aiming to develop a rapid biosensor detecting E. coli and Salmonella simultaneously, addressing a critical food safety gap in Southeast Asia.

archTIS delivered a 231% year-on-year increase in annual recurring revenue to A$15.1 million, marked by the full deployment of its US Department of Defense custom software and a significant contract with a US-European military alliance.

Nexsen Limited has cleared a major FDA regulatory hurdle for its StrepSure rapid Group B Streptococcus test, confirmed a clear 510(k) submission pathway, and secured over A$1.7 million in non-dilutive grants to expand clinical validation and market rollout in Asia-Pacific and neonatal diagnostics.

Icetana AI reported a 51% year-on-year jump in annual recurring revenue to $2.6 million but faced a $1.2 million net operating cash outflow in Q3 FY26, prompting plans for a capital raise amid expected cash flow improvements.

De.mem Limited has extended its growth streak with record quarterly cash receipts of approximately $10.4 million, a 31% increase year-on-year, alongside positive operating cash flow of $504,000 for the March 2026 quarter.